| Literature DB >> 23049609 |
Yu Wang1, You-Ping Hu, Wen-Chun Wang, Ri-Zhao Pang, An-Ren Zhang.
Abstract
The objective of this study was to assess the efficacy and safety of electroacupuncture in 138 patients with earthquake-caused PTSD using Randomized Controlled Trials (RCTs). 138 cases enrolled were randomly assigned to an electro-acupuncture group and a paroxetine group. The electro-acupuncture group was treated by scalp electro-acupuncture on Baihui (GV 20), Sishencong (EX-HN 1), Shenting (GV 24), and Fengchi (GB 20), and the paroxetine group was treated with simple oral administration of paroxetine. The efficacy and safety of the electro-acupuncture on treatment of 69 PTSD patients were evaluated using Clinician-Administered PTSD Scale (CAPS), Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), and Treatment Emergent Symptom Scale (TESS) according to clinical data. The total scores of CAPS, HAMD, and HAMA in the two groups after treatment showed significant efficacy compared to those before treatment. The comparison of reduction in the scores of CAPS, HAMD, and HAMA between the two groups suggested that the efficacy in the treated group was better than that in the paroxetine group. The present study suggested that the electro-acupuncture and paroxetine groups have significant changes in test PTSD, but the electro-acupuncture 2 group was more significant.Entities:
Year: 2012 PMID: 23049609 PMCID: PMC3462425 DOI: 10.1155/2012/431279
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1The locations of Baihui (GV 20), Sishencong (Ex-HN), Shenting (GV 24), and Fengchi (GB 20).
Participant characteristics of the two groups.
| Characteristic | Paroxetine | Electroacupuncture |
|
|---|---|---|---|
| Sex number (%) men | 28 (43.7) | 26 (40) | 0.778 |
| Sex number (%) women | 36 (56.3) | 39 (60) | |
| Age, mean (SD) | 50.3 ± 12.3 | 48.3 ± 13.3 | 0.562 |
Figure 2Flow chart of the study sample.
Comparison of scores in CAPS, HAMA, and HAMD before and after treatment.
| Score | Time/group | Before | 6 weeks | 12 weeks | 3-month followup | 6-month followup |
|
|---|---|---|---|---|---|---|---|
| CAPS | Paroxetine ( | 66.8 ± 21.3 | 44.7 ± 22.4 | 31.2 ± 18.9 | 26.3 ± 19.4 | 21.8 ± 18.7 |
|
| Treatment ( | 65.8 ± 19.7 | 39 ± 20.3 | 27.3 ± 17.9 | 20.4 ± 15.5 | 15.9 ± 14.3 |
| |
|
|
|
| |||||
|
| |||||||
| HAMD | Paroxetine ( | 12.7 ± 5.2 | 8.38 ± 4.28 | 6.11 ± 3.89 | 4.88 ± 3.65 | 4.25 ± 3.62 |
|
| Treatment ( | 13.1 ± 5.56 | 7.69 ± 4.44 | 5.22 ± 3.86 | 3.69 ± 3.06 | 2.98 ± 2.99 |
| |
|
|
|
| |||||
|
| |||||||
| HAMA | Paroxetine ( | 11.7 ± 5.85 | 7.61 ± 3.86 | 5.59 ± 3.18 | 4.70 ± 3.2 | 3.86 ± 3.15 |
|
| Treatment ( | 11.6 ± 5.11 | 6.38 ± 3.53 | 4.65 ± 3.44 | 3.46 ± 2.94 | 2.95 ± 2.85 |
| |
|
|
|
| |||||
Note: afor the intergroup comparison; bfor the intragroup comparison.
Comparison of reduction rate in CAPS, HAMA, and HAMD before and after treatment.
| Score | Time/group | 6 weeks | 12 weeks | 3-month followup | 6-month followup |
|
|---|---|---|---|---|---|---|
| CAPS | Control ( | 33.3 ± 25.5 | 54 ± 21.2 | 61.7 ± 22.1 | 68.6 ± 22.4 |
|
| Treatment ( | 41.9 ± 22.2 | 60.3 ± 20.8 | 70.4 ± 18.3 | 77.2 ± 17.1 |
| |
|
|
|
| ||||
|
| ||||||
| HAMD | Control ( | 31.4 ± 25.9 | 49.4 ± 27.9 | 59.6 ± 28.7 | 64.1 ± 31.8 |
|
| Treatment ( | 39.8 ± 26.1 | 59 ± 28.1 | 70.7 ± 21.7 | 77.1 ± 20.1 |
| |
|
|
|
| ||||
|
| ||||||
| HAMA | Control ( | 29.9 ± 25 | 46.1 ± 29.8 | 52 ± 36.2 | 60.9 ± 32.9 |
|
| Treatment ( | 40.5 ± 25.5 | 57.4 ± 26.7 | 68.8 ± 21.7 | 74 ± 20.4 |
| |
|
|
|
| ||||
Note: athe intergroup comparison; bthe intragroup comparison.